CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Insulin glulisine +1 moredrug
Likely dose
Insulin glulisine 20 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01436045
NCT01436045Phase 2Completed
CompareCT.gov

A Double-Blind, Placebo-Controlled Single Dose Study of the Safety and Efficacy of Glulisine on Cognitive Function and Memory in Individuals Diagnosed With Probable Mild to Moderate Alzheimer's Disease/Intranasal Insulin Study.

HealthPartners Institute·interventional·Posted Sep 19, 2011·Updated Oct 19, 2015

In Brief

A Phase 2 clinical trial evaluating Insulin glulisine and Saline for Alzheimer's Disease. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the effect of the rapidly acting intranasal insulin derivative (glulisine) on memory and cognition in 12 patients suffering from mild-moderate Alzheimer's Disease (AD) using a double-blind placebo-controlled single dose study. This study will further assess safety of insulin glulisine as well as the effects of this drug on olfaction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 19, 2011
Enrollment StartSep 1, 2011
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.8 years ago

Interventions

Insulin glulisinedrug

Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)

Salinedrug

Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)